Outlook: Network pharmacology coming of age
e-Therapeutics is pioneering the concept of network pharmacology, a novel approach that could revolutionise drug discovery. The two lead programmes, ETS2101 (dexanabinol) in various cancers and ETS6103 (tramadol) in major depressive disorder, are progressing through early-stage clinical trials with important results due during 2015. The significant investment in the discovery platform appears to be paying off, as a raft of novel potential leads have been identified. The company is well funded, through to 2019, which encompasses a number of value inflection points.E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.